Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines - Test2 - elhamkhani - TriplyDB

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines

http://www.wikidata.org/entity/Q28290236

about

Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia.Managing Cognitive Load to Uncover an Unusual Cause of Syncope: Exercises in Clinical Reasoning.Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: my way.Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management.Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.New developments in the management of Waldenström macroglobulinemia Diagnosis and management of neuropathies associated with plasma cell dyscrasias.Waldenstrom macroglobulinemia: prognosis and management.Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications.The high cost of cancer drugs and what we can do about it.Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.How to manage Waldenstrom's macroglobulinemia.Candidate genes of Waldenström's macroglobulinemia: current evidence and research.Three-dimensional Nuclear Telomere Organization in Multiple Myeloma.Hematopoietic cell transplantation for Waldenström macroglobulinemia.Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique.Rituximab: current status as therapy for malignant and benign hematologic disorders.Molecular pathogenesis of Waldenstrom's macroglobulinemia.Waldenström macroglobulinaemia: the key questions.Genetic factors and pathogenesis of Waldenström's macroglobulinemia.The use of therapeutic apheresis in cardiovascular disease.Therapeutic apheresis for patients with cancer.Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia.Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.Current options to manage Waldenström's macroglobulinemia.An unusual case of Waldenstrom's macroglobulinemia presented with nasopharyngeal involvement.Waldenström's macroglobulinemia: The role of hospital transfusion medicine laboratory in the diagnosis and management.Rituximab Improves Subclinical Temporal Dispersion of Distal Compound Muscle Action Potential in Anti-MAG/SGPG Neuropathy Associated with Waldenström Macroglobulinemia: A Case Report.Exertional Chest Pain and Dyspnea From Hyperviscosity Syndrome Related to Marginal Zone Lymphoma.Waldenstrom's Macroglobulinemia: An Update.Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

P2860

Q27314737-EF42FCC2-AC20-4B4B-9021-5DCCAB0311FD Q30276550-99F0A67E-4ECB-4B75-BE15-C086E0811266 Q30848149-D9081D24-171B-4E2A-928B-E8389D72BA36 Q33166423-11C7DE15-4630-4643-ABE2-57D7CE3C5A96 Q33395066-3530C7DD-6391-4853-9127-E66FDCE6A918 Q33400780-314ED14B-2EA5-43E4-8D68-F32B87A1724D Q33402669-536F9852-B529-4B9A-8AD4-AB17A00D5C46 Q33408517-274BEB48-E065-42F5-A868-6949AD5DF6A9 Q33421444-377E4CFE-EE4A-4D9C-A9E3-C68148640CFC Q33438490-F468FA4C-42C2-4458-ACE9-DFCEACCA42FC Q34553880-CEDC47B8-4456-4465-9A41-B0A8BCB9B35E Q34555067-D50ED0B5-6C63-4745-991D-936DF7F0EAA4 Q35244911-A80FBE64-7A49-4174-8EAB-BAB8FE8134C5 Q35597598-1B710282-A76A-4B30-9EA2-B2B955409816 Q36512856-A48B581D-52E6-4BCC-9AE7-5A371478FE35 Q36533710-537A77A5-C83D-4DC0-8EB8-284F39950822 Q36764811-0D034BFB-BD2C-4DD0-AEB8-E65A1F1DA856 Q37074275-CB98AEEE-E537-42D2-82B5-C7435B321BED Q37474404-0776B8BC-4FD5-4F36-8DB3-5B71BFA2C5C1 Q37875673-D24F4342-3AF7-4E01-819E-5A5968D389EB Q37923308-650F3055-710B-4A60-B073-21E702A87312 Q37984551-4A62F60C-3177-4CFF-B4B0-01245B41D24E Q38024773-2BF25321-C71A-4FC0-9C4B-C1017730CFCF Q38104808-3AC762C4-92DA-431F-BC53-D63C6B434840 Q38125430-20DA32D9-B523-465B-BDE3-FBA556EE0B97 Q38203567-78E64935-9F23-4FCA-A7C6-AB7735CAF057 Q38287610-F9D57B8D-7C50-487D-AD27-EBEE65AFD26E Q38644775-A14D7A4A-3B83-4CAA-8EB8-DD978F4879DE Q38760522-532D228C-C718-4A7A-9ACB-019871930224 Q38774535-0620B8F5-35DF-4B4F-AAFB-A243551EAE93 Q38895818-D6AACD39-9B5F-4E5E-8F50-F62F7DE8AEA3 Q38970612-8B0908FA-656A-4310-836D-85F63C228BE2 Q39044362-0B8BDBFA-36F3-49C4-AC2A-1648EFB54BAC Q39358109-49BCDFC8-F820-41AC-9EF7-08DB5BE28FAF Q40230100-4447D791-ABDA-4E3B-9297-67E79EB099F1 Q42143183-D2DDCEDB-8CA2-4A3E-8823-9168DFDBF6E9 Q43221190-C7FB2434-D52D-43C9-AD01-C2A755109750 Q45854126-C9CDCE4B-7876-4536-9EC4-7F45A848A544 Q47736653-A2C38257-993D-46A6-962B-8594D5CB717D Q51199274-5307479A-6718-4AB0-8F2B-96A6CB499575

P2860

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines

http://www.wikidata.org/entity/Q28290236

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Diagnosis and management of Wa ...... ed therapy (mSMART) guidelines

@ast

Diagnosis and management of Wa ...... ed therapy (mSMART) guidelines

@en

Diagnosis and management of Wa ...... ed therapy (mSMART) guidelines

@nl

type

label

Diagnosis and management of Wa ...... ed therapy (mSMART) guidelines

@ast

Diagnosis and management of Wa ...... ed therapy (mSMART) guidelines

@en

Diagnosis and management of Wa ...... ed therapy (mSMART) guidelines

@nl

prefLabel

Diagnosis and management of Wa ...... ed therapy (mSMART) guidelines

@ast

Diagnosis and management of Wa ...... ed therapy (mSMART) guidelines

@en

Diagnosis and management of Wa ...... ed therapy (mSMART) guidelines

@nl

P1433

Q28290236-7321DA09-076B-49B4-96D0-59C3EBD7EE97

P1476

Q28290236-A10F6BF5-B770-41B1-9150-3C379B0F6EE8

P2093

Q28290236-0675696E-B39D-4F69-A41C-7C59C7D49981

Q28290236-16E7C848-D21C-4573-A0FC-B091BDE3C090

Q28290236-1A31B217-C4EF-492F-A9C7-13995AC0A46C

Q28290236-1BA6FA19-8AE4-4BAA-8F2D-6A4D845A4602

Q28290236-24653332-E47B-4E4D-9FA6-DA18D0DDCF38

Q28290236-2515347C-9A6D-4913-A55D-83C4B27297AD

Q28290236-2F65F6BC-544C-4B43-A9F7-0E3DC88150C1

Q28290236-32B1DCEC-F93A-4885-93A6-FD4323CE7718

Q28290236-5080CB5B-15C2-4655-9675-B18569A49B57

Q28290236-5C111D9E-137E-4A0A-8E6B-B98B5F5137B7

P2860

Q28290236-0204D158-F72A-496F-9287-B521C892F083

Q28290236-04D57482-BCB5-4B8B-A9BB-5FF4C6064458

Q28290236-0538E177-80B9-4DD6-A46E-BB117BB376FD

Q28290236-11496FCF-A199-4065-B1C0-27ADB74143A2

Q28290236-12F38C02-2381-4F01-892B-9CE82EE409B6

Q28290236-157F41B0-6FF6-48C7-8539-D0BD7190E477

Q28290236-170B24D2-9CBD-45DC-9186-831F7D9D80DE

Q28290236-19AB95F3-9340-478C-91FA-75B5A636A361

Q28290236-267FF0EA-0A3E-47CE-A7F8-8141094D82D0

Q28290236-2787418E-F7F4-4B1E-8A1F-E22084DFB657

P304

Q28290236-0ADF889E-C75F-4E1E-A8C5-CBE3DCF718B9

P31

Q28290236-0756797D-1B3E-460C-B4CE-79BB1604AA63

P356

Q28290236-6B1169CB-2071-4BC1-8815-B33A40E5F7B4

P407

Q28290236-43DADD9F-F72D-492F-A5C9-5DABBC5A8F4A

P433

Q28290236-A97D6B56-BCE7-429A-93E9-FE7213BEC0CA

P478

Q28290236-F3F0C26F-4A2A-49D8-8162-0B6FA984FD3F

P50

Q28290236-11C3F336-C944-4E3C-9945-1D0B39F2DA2B

Q28290236-2F390394-FD6F-49CE-B91D-9FAE714B5AD9

Q28290236-3AE36FC8-98D0-4C6A-A065-82DF5E9B6918

Q28290236-3D22D3FF-0303-44CF-8286-B7C65C4A4CB0

Q28290236-41ECB611-C2C8-4590-9C4A-0A24D93F897F

Q28290236-72A89E36-A66B-420C-869D-C414BE9D819E

Q28290236-A8EE6999-1C35-4D71-8A47-C7EC024CE2B6

Q28290236-AAF01DE0-267C-479C-9854-922171F3CC19

Q28290236-BA4F9EBD-74BC-40C9-96A3-A62D80776DA3

P577

Q28290236-A4BC2331-2AD5-412B-9878-538FC123A6A3

P5875

Q28290236-16801F8E-91D0-4D66-8243-C396D1F4BF1B

P698

Q28290236-E1E39E74-B173-4329-9937-285CF0970919

P921

Q28290236-60754bf2-b71d-41b2-b4e7-9c7680764f23

P932

Q28290236-5BEDB25B-88BA-4DD4-AA14-9A32BDDAC165

P356

P1433

Mayo Clinic Proceedings

P1476

Diagnosis and management of Wa ...... ed therapy (mSMART) guidelines

@en

P2093

A Keith Stewart

http://www.w3.org/2001/XMLSchema#string

Carrie A Thompson

http://www.w3.org/2001/XMLSchema#string

Craig B Reeder

http://www.w3.org/2001/XMLSchema#string

David J Inwards

http://www.w3.org/2001/XMLSchema#string

Francis K Buadi

http://www.w3.org/2001/XMLSchema#string

Grzegorz S Nowakowski

http://www.w3.org/2001/XMLSchema#string

Ivana N M Micallef

http://www.w3.org/2001/XMLSchema#string

John A Lust

http://www.w3.org/2001/XMLSchema#string

Joseph P Colgan

http://www.w3.org/2001/XMLSchema#string

Joseph R Mikhael

http://www.w3.org/2001/XMLSchema#string

P2860

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Myeloma and race: a review of the literature

Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

Diagnosis and management of Waldenstrom's macroglobulinemia

Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia

6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance

Effect of a 2-hour infusion of 2-chlorodeoxyadenosine in the treatment of refractory or previously untreated Waldenström's macroglobulinemia.

Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma.

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma.

Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia.

P304

824-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4065/MCP.2010.0304

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Angela Dispenzieri

Stephen J Russell

S. Vincent Rajkumar

Suzanne R Hayman

Steven R Zeldenrust

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45629676

http://www.w3.org/2001/XMLSchema#string

P698

20702770

http://www.w3.org/2001/XMLSchema#string

P921

P932

2931618

http://www.w3.org/2001/XMLSchema#string